FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Vaccine2014; 32(29); 3670-3674; doi: 10.1016/j.vaccine.2014.04.036

Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.

Abstract: African horse sickness virus (AHSV) is an arthropod-borne pathogen that infects all species of equidae and causes high mortality in horses. Previously, a recombinant modified vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 was shown to induce virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR -/-) against virulent AHSV challenge. This study builds on the previous work, examining the protective efficacy of MVA-VP2 vaccination in the natural host of AHSV infection. A study group of 4 horses was vaccinated twice with a recombinant MVA virus expressing the major capsid protein (VP2) of AHSV serotype 9. Vaccinated animals and a control group of unvaccinated horses were then challenged with a virulent strain of AHSV-9. The vaccinated animals were completely protected against clinical disease and also against viraemia as measured by standard end-point dilution assays. In contrast, all control horses presented viraemia after challenge and succumbed to the infection. These results demonstrate the potential of recombinant MVA viruses expressing the outer capsid VP2 of AHSV as a protective vaccine against AHSV infection in the field.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
Get Full Text
Publication Date: 2014-05-14 PubMed ID: 24837765PubMed Central: PMC4061461DOI: 10.1016/j.vaccine.2014.04.036Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research discusses the effective use of a genetically modified virus, called MVA-VP2, for protecting horses against the deadly African horse sickness virus (AHSV). The study found that horses vaccinated with MVA-VP2 were completely shielded from the disease, unlike the unvaccinated ones which all contracted the infection.

About African horse sickness virus (AHSV)

  • AHSV is a deadly pathogen carried by arthropods that infects all equidae species and results in high mortality rates in horses.
  • Earlier, a recombinant modified vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 showed promising results by generating virus neutralising antibodies in horses, and protection to mice genetically engineered to lack an interferon alpha receptor gene (IFNAR -/-) against virulent AHSV.

The Study Details

  • Building on previous discoveries, this research aimed to check the protective effectiveness of MVA-VP2 vaccination in horses, which are the natural hosts of AHSV infection.
  • The study involved four horses that received two injections of a recombinant MVA virus, which expressed the major capsid protein (VP2) of AHSV serotype 9.

The Study Findings

  • Upon exposure to a virulent strain of AHSV-9, the vaccinated animals showed complete protection against both clinical disease and viraemia, as gauged by standard end-point dilution assays.
  • Contrarily, the horses that weren’t vaccinated exhibited signs of viraemia after exposure and eventually succumbed to the infection.
  • These findings clearly suggest the potential of the recombinant MVA-VP2 as an effective vaccine against AHSV infection.

Conclusion

  • The study yielded valuable insights into the potential use of a recombinant MVA virus to provide horses complete protection against African horse sickness. It paves the way for effective vaccine measures that may save equidae species from falling prey to this deadly infection.

Cite This Article

APA
Alberca B, Bachanek-Bankowska K, Cabana M, Calvo-Pinilla E, Viaplana E, Frost L, Gubbins S, Urniza A, Mertens P, Castillo-Olivares J. (2014). Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge. Vaccine, 32(29), 3670-3674. https://doi.org/10.1016/j.vaccine.2014.04.036

Publication

Vaccine
ISSN: 1873-2518
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 32
Issue: 29
Pages: 3670-3674

Researcher Affiliations

Alberca, Berta
  • Zoetis-Spain, Ctra de Comprodon, Finca La Riba, 17813 Vall de Bianya, Girona, Spain.
Bachanek-Bankowska, Katarzyna
  • The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, Surrey, UK.
Cabana, Marta
  • Zoetis-Spain, Ctra de Comprodon, Finca La Riba, 17813 Vall de Bianya, Girona, Spain.
Calvo-Pinilla, Eva
  • The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, Surrey, UK.
Viaplana, Elisenda
  • Zoetis-Spain, Ctra de Comprodon, Finca La Riba, 17813 Vall de Bianya, Girona, Spain.
Frost, Lorraine
  • The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, Surrey, UK.
Gubbins, Simon
  • The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, Surrey, UK.
Urniza, Alicia
  • Zoetis-Spain, Ctra de Comprodon, Finca La Riba, 17813 Vall de Bianya, Girona, Spain.
Mertens, Peter
  • The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, Surrey, UK.
Castillo-Olivares, Javier
  • The Pirbright Institute, Ash Road, Pirbright, Woking GU24 0NF, Surrey, UK. Electronic address: javier.castillo-olivares@pirbright.ac.uk.

MeSH Terms

  • African Horse Sickness / prevention & control
  • Animals
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood
  • Capsid Proteins / immunology
  • Female
  • Horses / immunology
  • Male
  • Neutralization Tests
  • Vaccines, Synthetic / immunology
  • Vaccinia virus / genetics
  • Viral Vaccines / immunology
  • Viremia / prevention & control

References

This article includes 26 references
  1. Rodriguez M, Hooghuis H, Castano M. African horse sickness in Spain.. Vet Microbiol 1992;33(1–4):129–142.
    pubmed: 1481352
  2. Sanchez-Vizcaino JM. Control and eradication of African horse sickness with vaccine.. Dev Biol (Basel) 2004;119:255–258.
    pubmed: 15742636
  3. Coetzer JAW, Guthrie AJ. African horse sickness.. 2004. pp. 1231–1246.
  4. Mellor PS, Hamblin C. African horse sickness.. Vet Res 2004;35(4):445–466.
    pubmed: 15236676
  5. Erasmus BJ. A new apporach to polyvalent immunization against African horse sickness.. 1978.
  6. von Teichman BF, Dungu B, Smit TK. In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6.. Vaccine 2010;28(39):6505–6517.
    pubmed: 20638456
  7. House JA, Lombard M, Dubourget P, House C, Mebus CA. Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine.. Vaccine 1994;12(2):142–144.
    pubmed: 8147096
  8. Mirchamsy H, Taslimi H. Inactivated African horse sickness virus cell culture vaccine.. Immunology 1968;14(1):81–88.
    pmc: PMC1409248pubmed: 5635756
  9. Ozawa Y, Bahrami S. African horse-sickness killed-virus tissue culture vaccine.. Can J Comp Med Vet Sci 1966;30(11):311–314.
    pmc: PMC1494603pubmed: 4226381
  10. Roy P, Sutton G. New generation of African horse sickness virus vaccines based on structural and molecular studies of the virus particles.. Arch Virol Suppl 1998;14:177–202.
    pubmed: 9785506
  11. Romito M, Du Plessis DH, Viljoen GJ. Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus.. Onderstepoort J Vet Res 1999;66(2):139–144.
    pubmed: 10486832
  12. Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, Maan S. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR −/− mouse model.. PLoS One 2011;6(1):e16503.
    pmc: PMC3027694pubmed: 21298069
  13. Chiam R, Sharp E, Maan S, Rao S, Mertens P, Blacklaws B. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA). PLoS One 2009;4(6):e5997.
    pmc: PMC2694985pubmed: 19543394
  14. Guthrie AJ, Quan M, Lourens CW, Audonnet JC, Minke JM, Yao J. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.. Vaccine 2009;27(33):4434–4438.
    pubmed: 19490959
  15. Chakrabarti S, Brechling K, Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.. Mol Cell Biol 1985;5(12):3403–3409.
    pmc: PMC369169pubmed: 3939316
  16. Schaefer-Klein J, Givol I, Barsov EV, Whitcomb JM, VanBrocklin M, Foster DN. The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors.. Virology 1998;248(2):305–311.
    pubmed: 9721239
  17. OIE. African horse sickness.. Manual of diagnostic tests and vaccines for terrestrial animals 2013 2013. pp. 7–8.
  18. Karber G. Beitrag zur kollektiven behandlung pharmakologischer reihenversuche.. Naunyn-Schmiedebergs Arch Exp Pathol Pharmakol 1931;162:480–483.
  19. Aguero M, Gomez-Tejedor C, Angeles Cubillo M, Rubio C, Romero E, Jimenez-Clavero A. Real-time fluorogenic reverse transcription polymerase chain reaction assay for detection of African horse sickness virus.. J Vet Diagn Invest 2008;20(3):325–328.
    pubmed: 18460619
  20. Stone-Marschat MA, Moss SR, Burrage TG, Barber ML, Roy P, Laegreid WW. Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.. Virology 1996;220(1):219–222.
    pubmed: 8659117
  21. El Garch H, Crafford JE, Amouyal P, Durand PY, Edlund Toulemonde C, Lemaitre L. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.. Vet Immunol Immunopathol 2012;149(1–2):76–85.
    pubmed: 22763149
  22. Calvo-Pinilla E, de la Poza F, Gubbins S, Mertens PP, Ortego J, Castillo-Olivares J. Vaccination of mice with a modified vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.. Virus Res 2013;180:23–30.
    pubmed: 24333835
  23. Burrage TG, Laegreid WW. African horsesickness: pathogenesis and immunity.. Comp Immunol Microbiol Infect Dis 1994;17(3–4):275–285.
    pubmed: 8001349
  24. Quan M, Lourens CW, MacLachlan NJ, Gardner IA, Guthrie AJ. Development and optimisation of a duplex real-time reverse transcription quantitative PCR assay targeting the VP7 and NS2 genes of African horse sickness virus.. J Virol Methods 2010;167(1):45–52.
    pubmed: 20304015
  25. Scanlen M, Paweska JT, Verschoor JA, van Dijk AA. The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant.. Vaccine 2002;20(7–8):1079–1088.
    pubmed: 11803068
  26. Martinez-Torrecuadrada JL, Diaz-Laviada M, Roy P, Sanchez C, Vela C, Sanchez-Vizcaino JM. Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.. J Gen Virol 1996;77(Pt 6):1211–1221.
    pubmed: 8683209

Citations

This article has been cited 30 times.
  1. Ma X, Zhang M, Zhang X, Qi T, Zhang W, Zhao Y, Na L, Zhang Y, Wang XF, Wang X. Construction and Immunogenicity Evaluation of a Recombinant Fowlpox Virus Expressing VP2 Gene of African Horse Sickness Virus Serotype 1. Microorganisms 2025 Dec 9;13(12).
    doi: 10.3390/microorganisms13122807pubmed: 41472010google scholar: lookup
  2. Ma X, Zhang Y, Na L, Qi T, Ma W, Guo X, Wang XF, Wang X. Identification and Characterization of Linear Epitopes of Monoclonal Antibodies Against African Horse Sickness Virus Serotype 1 VP2 Protein. Viruses 2024 Nov 15;16(11).
    doi: 10.3390/v16111780pubmed: 39599893google scholar: lookup
  3. Pitchers KG, Boakye OD, Campeotto I, Daly JM. The Potential of Plant-Produced Virus-like Particle Vaccines for African Horse Sickness and Other Equine Orbiviruses. Pathogens 2024 May 28;13(6).
    doi: 10.3390/pathogens13060458pubmed: 38921755google scholar: lookup
  4. O'Kennedy MM, Roth R, Ebersohn K, du Plessis LH, Mamputha S, Rutkowska DA, du Preez I, Verschoor JA, Lemmer Y. Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice. PLoS One 2024;19(4):e0301340.
    doi: 10.1371/journal.pone.0301340pubmed: 38625924google scholar: lookup
  5. Calvo-Pinilla E, Jiménez-Cabello L, Utrilla-Trigo S, Illescas-Amo M, Ortego J. Cytokine mRNA Expression Profile in Target Organs of IFNAR (-/-) Mice Infected with African Horse Sickness Virus. Int J Mol Sci 2024 Feb 8;25(4).
    doi: 10.3390/ijms25042065pubmed: 38396742google scholar: lookup
  6. Jones LM, Hawes PC, Salguero FJ, Castillo-Olivares J. Pathological features of African horse sickness virus infection in IFNAR(-/-) mice. Front Vet Sci 2023;10:1114240.
    doi: 10.3389/fvets.2023.1114240pubmed: 37065248google scholar: lookup
  7. Orlova OV, Glazkova DV, Bogoslovskaya EV, Shipulin GA, Yudin SM. Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications. Vaccines (Basel) 2022 Sep 13;10(9).
    doi: 10.3390/vaccines10091516pubmed: 36146594google scholar: lookup
  8. Durán-Ferrer M, Villalba R, Fernández-Pacheco P, Tena-Tomás C, Jiménez-Clavero MÁ, Bouzada JA, Ruano MJ, Fernández-Pinero J, Arias M, Castillo-Olivares J, Agüero M. Clinical, Virological and Immunological Responses after Experimental Infection with African Horse Sickness Virus Serotype 9 in Immunologically Naïve and Vaccinated Horses. Viruses 2022 Jul 15;14(7).
    doi: 10.3390/v14071545pubmed: 35891525google scholar: lookup
  9. Marín-López A, Utrilla-Trigo S, Jiménez-Cabello L, Ortego J. Recombinant Modified Vaccinia Virus Ankara Development to Express VP2, NS1, and VP7 Proteins of Bluetongue Virus. Methods Mol Biol 2022;2465:177-193.
    doi: 10.1007/978-1-0716-2168-4_10pubmed: 35118622google scholar: lookup
  10. Fairbanks EL, Brennan ML, Mertens PPC, Tildesley MJ, Daly JM. Re-parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search. Transbound Emerg Dis 2022 Jul;69(4):e671-e681.
    doi: 10.1111/tbed.14420pubmed: 34921513google scholar: lookup
  11. Sullivan E, Lecollinet S, Kerviel A, Hue E, Pronost S, Beck C, Dumarest M, Zientara S, Roy P. Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes. Vaccine 2021 May 27;39(23):3161-3168.
    doi: 10.1016/j.vaccine.2021.04.034pubmed: 33958224google scholar: lookup
  12. Castillo-Olivares J. African horse sickness in Thailand: Challenges of controlling an outbreak by vaccination. Equine Vet J 2021 Jan;53(1):9-14.
    doi: 10.1111/evj.13353pubmed: 33007121google scholar: lookup
  13. Rodríguez M, Joseph S, Pfeffer M, Raghavan R, Wernery U. Immune response of horses to inactivated African horse sickness vaccines. BMC Vet Res 2020 Sep 1;16(1):322.
    doi: 10.1186/s12917-020-02540-ypubmed: 32873300google scholar: lookup
  14. Calvo-Pinilla E, Marín-López A, Utrilla-Trigo S, Jiménez-Cabello L, Ortego J. Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design. Curr Opin Virol 2020 Oct;44:49-56.
    doi: 10.1016/j.coviro.2020.06.003pubmed: 32659516google scholar: lookup
  15. Rutkowska DA, Mokoena NB, Tsekoa TL, Dibakwane VS, O'Kennedy MM. Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness. BMC Vet Res 2019 Dec 3;15(1):432.
    doi: 10.1186/s12917-019-2184-2pubmed: 31796116google scholar: lookup
  16. Dennis SJ, Meyers AE, Hitzeroth II, Rybicki EP. African Horse Sickness: A Review of Current Understanding and Vaccine Development. Viruses 2019 Sep 11;11(9).
    doi: 10.3390/v11090844pubmed: 31514299google scholar: lookup
  17. Marín-Lopez A, Calvo-Pinilla E, Moreno S, Utrilla-Trigo S, Nogales A, Brun A, Fikrig E, Ortego J. Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor. Viruses 2019 Jan 8;11(1).
    doi: 10.3390/v11010035pubmed: 30625992google scholar: lookup
  18. Aksular M, Calvo-Pinilla E, Marín-López A, Ortego J, Chambers AC, King LA, Castillo-Olivares J. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model. Vaccine 2018 Nov 12;36(46):7003-7010.
    doi: 10.1016/j.vaccine.2018.09.065pubmed: 30309744google scholar: lookup
  19. Durán-Ferrer M, Agüero M, Zientara S, Beck C, Lecollinet S, Sailleau C, Smith S, Potgieter C, Rueda P, Sastre P, Monaco F, Villalba R, Tena-Tomás C, Batten C, Frost L, Flannery J, Gubbins S, Lubisi BA, Sánchez-Vizcaíno JM, Emery M, Sturgill T, Ostlund E, Castillo-Olivares J. Assessment of reproducibility of a VP7 Blocking ELISA diagnostic test for African horse sickness. Transbound Emerg Dis 2019 Jan;66(1):83-90.
    doi: 10.1111/tbed.12968pubmed: 30070433google scholar: lookup
  20. Calvo-Pinilla E, Gubbins S, Mertens P, Ortego J, Castillo-Olivares J. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host. Antiviral Res 2018 Jun;154:132-139.
    doi: 10.1016/j.antiviral.2018.04.015pubmed: 29678552google scholar: lookup
  21. Okeke MI, Okoli AS, Diaz D, Offor C, Oludotun TG, Tryland M, Bøhn T, Moens U. Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?. Viruses 2017 Oct 29;9(11).
    doi: 10.3390/v9110318pubmed: 29109380google scholar: lookup
  22. Dennis SJ, Meyers AE, Guthrie AJ, Hitzeroth II, Rybicki EP. Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine. Plant Biotechnol J 2018 Feb;16(2):442-450.
    doi: 10.1111/pbi.12783pubmed: 28650085google scholar: lookup
  23. Lulla V, Losada A, Lecollinet S, Kerviel A, Lilin T, Sailleau C, Beck C, Zientara S, Roy P. Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge. Vaccine 2017 Jul 24;35(33):4262-4269.
    doi: 10.1016/j.vaccine.2017.06.023pubmed: 28625521google scholar: lookup
  24. Mathebula EM, Faber FE, Van Wyngaardt W, Van Schalkwyk A, Pretorius A, Fehrsen J. B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera. Onderstepoort J Vet Res 2017 Feb 24;84(1):e1-e12.
    doi: 10.4102/ojvr.v84i1.1313pubmed: 28281773google scholar: lookup
  25. Conradie AM, Stassen L, Huismans H, Potgieter CA, Theron J. Establishment of different plasmid only-based reverse genetics systems for the recovery of African horse sickness virus. Virology 2016 Dec;499:144-155.
    doi: 10.1016/j.virol.2016.07.010pubmed: 27657835google scholar: lookup
  26. Weyer CT, Grewar JD, Burger P, Rossouw E, Lourens C, Joone C, le Grange M, Coetzee P, Venter E, Martin DP, MacLachlan NJ, Guthrie AJ. African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004-2014. Emerg Infect Dis 2016 Dec;22(12):2087-2096.
    doi: 10.3201/eid2212.160718pubmed: 27442883google scholar: lookup
  27. Lulla V, Lulla A, Wernike K, Aebischer A, Beer M, Roy P. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes. J Virol 2016 Aug 15;90(16):7405-7414.
    doi: 10.1128/JVI.00548-16pubmed: 27279609google scholar: lookup
  28. van de Water SG, van Gennip RG, Potgieter CA, Wright IM, van Rijn PA. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV. J Virol 2015 Sep;89(17):8764-72.
    doi: 10.1128/JVI.01052-15pubmed: 26063433google scholar: lookup
  29. Calvo-Pinilla E, de la Poza F, Gubbins S, Mertens PP, Ortego J, Castillo-Olivares J. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge. Antiviral Res 2015 Apr;116:27-33.
    doi: 10.1016/j.antiviral.2015.01.009pubmed: 25643968google scholar: lookup
  30. Kanai Y, van Rijn PA, Maris-Veldhuis M, Kaname Y, Athmaram TN, Roy P. Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus. Vaccine 2014 Sep 3;32(39):4932-7.
    doi: 10.1016/j.vaccine.2014.07.031pubmed: 25045805google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.